|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||6.61 - 7.19|
|52 Week Range||6.61 - 25.90|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
Subscribe to Yahoo Finance Plus to view Fair Value for NYXH.BR
Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17th Annual Wells Fargo Securities Healthcare Conference, which takes p
The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 170.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Participating from the company today will be Olivier Taelman, chief executive officer; and Loic Moreau, chief financial officer. During the call, we will discuss our operating activities and review our second quarter financial results released after U.S. Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results or performance are forward-looking statements.